France Alcohol Addiction Therapeutics Market Analysis

France Alcohol Addiction Therapeutics Market Executive Summary

The France Alcohol Addiction Therapeutics Market is valued at around $20 Mn in 2022 and is projected to reach $30 Mn by 2030, exhibiting a CAGR of 5.3% during the forecast period.

Alcohol Addiction or Alcohol use disorder (AUD) is a chronic relapsing disorder characterized by compulsive alcohol consumption, a lack of control over intake, and the development of unpleasant emotional states when alcohol is unavailable. It is marked by a decreased capacity to reduce or quit alcohol consumption in the face of negative social, professional, or health outcomes. This illness falls within the continuum and can be mild, moderate, or severe. It includes problems that some people call alcohol abuse, alcohol dependence, or alcoholism informally. Options for treatment include antidotes, detoxification, abstinence, group therapy, and drugs that curb cravings, such as Naltrexone. The use of digital therapeutic platforms for support throughout the recovery process has grown in popularity

Known for its wine culture, France also has significant issues with alcohol addiction. In their lifetime, 9% of people report having an alcohol use disorder (AUD). Four males out of ten report excessive drinking, compared to one woman out of ten. Males are more impacted than women. Every year, alcohol use is blamed for 41,000 fatalities. Drivers in France with illegal blood alcohol content are involved in around 22% of fatal traffic accidents. The increasing public awareness of alcoholism, a rising number of cases, and growing government support, including healthcare financing and preventive laws, indicate a shifting societal attitude towards alcohol addiction in France

Medication sales are dominated by multinational pharmaceutical corporations such as AbbVie and Otsuka, although huge public hospital networks such as Hôpitaux Universitaires, with their business model, serve a sizable patient population by the provision of rehabilitation therapies

Market Dynamics

Market Drivers

Increased Awareness: Public awareness of alcoholism and its effects is growing as a result of government programs and media efforts. This motivates people to ask for assistance. Addiction-related stigma is gradually fading, which makes it simpler for people to seek treatment and talk freely about their issues. Getting therapy has become normal and people do not fear being judged.

Increasing Number of Cases: 5.7% of adults in France currently suffer from alcohol misuse, indicating a serious problem. Effective therapeutic alternatives are thus in high demand and are only becoming stronger. Concerning drinking patterns among young adults and teens, point to a possible rise in addiction cases in the future. Alcohol use rises due to cultural factors including the nation's wine culture, which makes people believe it is acceptable.

Support from the Government: With programs like more financing for healthcare services and reimbursement plans for certain drugs, government policies are starting to show more support for addiction treatment. Laws designed to prevent underage drinking and alcohol advertising aid in the growth of the industry.

Market Restraints

High Treatment Cost: Many useful drugs, such as long-acting naltrexone, can be costly, making them inaccessible to a significant proportion of the French population. Speaking with a therapist on your own may also be quite taxing, particularly for young individuals who don't have much money or insurance. This makes it more difficult to get these necessary therapies, especially when combined with some insurance plans' restricted coverage.

Healthcare System Fragmentation and Shortages: The French healthcare system is disjointed, with the public and private sectors providing varying degrees of coverage and treatment accessibility. People may find it difficult and confusing to navigate through this, which might result in missed opportunities to receive care. In France, especially in underprivileged regions, there is a severe lack of licensed addiction doctors and therapists.

Cultural Beliefs and Treatment Alternatives: In many groups, the acceptance and use of addiction therapy might be influenced by traditional ideas and attitudes around alcohol intake. Evidence-based therapies may face competition from traditional and informal therapy modalities like faith-based programs or herbal cures, which might affect their efficacy and accessibility.

Healthcare Policies and Regulatory Landscape

The Ministry of Social Affairs, Health, and Women's Rights is in charge of organizing and funding healthcare services, as well as developing the country's health strategy and carrying out public health policies. The French healthcare system is a national obligation. The majority of hospital, doctor, and long-term care expenses, as well as prescription medication expenditures, are covered by the French healthcare system; consumers are nonetheless liable for coinsurance, copayments, and any outstanding balances for physician charges that are above the covered amounts. The French drug regulatory body, the National Agency for the Safety of Medicines and Health Products (ANSM), is in charge of making sure that medical supplies sold in France are appropriate for use, safe, and effective. The ANSM conducts quality control of its products in its laboratories, approves new medications and biologics, keeps an eye on all health products during their entire life cycle, investigates the effects of their use, gathers and evaluates side effect reports, and inspects manufacturing and distribution facilities. Drugs can be authorized for sale at the national or European level by the ANSM, formerly the French Agency for the Safety of Health.

Competitive Landscape

Key Players

• Elli Lily
• Roche
• AbbVie
• Lundbeck
• Otsuka Pharmaceuticals
• Servier
• Ipsen
• Viatris
• Bioprojet